P09 Stock Overview Designs, develops, and manufactures sequencing solution to resolve genetically complex problems. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Pacific Biosciences of California, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Pacific Biosciences of California Historical stock prices Current Share Price US$1.77 52 Week High US$8.43 52 Week Low US$1.05 Beta 1.95 1 Month Change -1.01% 3 Month Change 9.27% 1 Year Change -80.01% 3 Year Change -89.68% 5 Year Change -60.66% Change since IPO -85.25%
Recent News & Updates
New minor risk - Shareholder dilution Nov 14
Third quarter 2024 earnings released: US$0.22 loss per share (vs US$0.26 loss in 3Q 2023) Nov 09
PacBio Unveils the Vega System Nov 07
PacBio Announces SPRQ Chemistry for Revio Sequencing Systems Oct 29
Pacific Biosciences of California, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 11
President recently sold €155k worth of stock Sep 19 See more updates
New minor risk - Shareholder dilution Nov 14
Third quarter 2024 earnings released: US$0.22 loss per share (vs US$0.26 loss in 3Q 2023) Nov 09
PacBio Unveils the Vega System Nov 07
PacBio Announces SPRQ Chemistry for Revio Sequencing Systems Oct 29
Pacific Biosciences of California, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 11
President recently sold €155k worth of stock Sep 19
Chief Operating Officer recently sold €57k worth of stock Aug 22 Pacific Biosciences of California, Inc. Reports Goodwill Impairment for the Second Quarter Ended June 30, 2024 Aug 08
Pacific Biosciences of California, Inc. to Report Q2, 2024 Results on Aug 07, 2024 Jul 16
Pacific Biosciences of California, Inc.(NasdaqGS:PACB) dropped from Russell 2500 Growth Index Jul 03
First quarter 2024 earnings released: US$0.29 loss per share (vs US$0.36 loss in 1Q 2023) May 11
Pacific Biosciences of California, Inc., Annual General Meeting, Jun 18, 2024 May 01
Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2024 Apr 16
PacBio Announces PureTarget Repeat Expansion Panel, Expanding Its Portfolio of End-To-End Clinical Research Solutions Mar 12
Insider recently bought €162k worth of stock Mar 07
Full year 2023 earnings released: US$1.21 loss per share (vs US$1.40 loss in FY 2022) Mar 04
President recently sold €445k worth of stock Feb 25
Full year 2023 earnings released: US$1.21 loss per share (vs US$1.40 loss in FY 2022) Feb 16
Pacific Biosciences of California, Inc Announces HiFi Prep Kit 96 and HiFi Plex Prep Kit 96 for Long-Read Sequencing Applications at Scale Feb 05
Pacific Biosciences of California, Inc. to Report Q4, 2023 Results on Feb 15, 2024 Jan 26
PacBio Announces New Nanobind Pandna Kit Enabling Hifi Optimized Dna Extraction Solutions Jan 15
Chief Operating Officer recently sold €221k worth of stock Jan 12
Pacific Biosciences of California, Inc. Announces Resignation of David Botstein from the Board Dec 12
PacBio Announces HiFi Solves, a Global Consortium of Clinical Genomics Research Leaders Nov 04
Third quarter 2023 earnings released: US$0.26 loss per share (vs US$0.34 loss in 3Q 2022) Nov 01
Pacific Biosciences of California, Inc. Appoints David Meline to Audit Committee Oct 28
Pacific Biosciences of California, Inc. Appoints David Meline to its Board of Directors Oct 17
Pacific Biosciences of California, Inc. to Report Q3, 2023 Results on Oct 30, 2023 Oct 13
Pacbio Announces Complete Computational Workflow for Human Whole Genome Sequencing Data Analysis Oct 12
President recently sold €918k worth of stock Sep 21
Chief Operating Officer recently sold €263k worth of stock Aug 20
Pacific Biosciences of California, Inc. (NasdaqGS:PACB) entered into an agreement to acquire Apton Biosystems, Inc. for approximately $110 million. Aug 04
Second quarter 2023 earnings released: US$0.28 loss per share (vs US$0.32 loss in 2Q 2022) Aug 03 Pacific Biosciences of California, Inc. (NasdaqGS:PACB) entered into an agreement to acquire Apton Biosystems, Inc. for $110 million.
Pacific Biosciences of California, Inc. to Report Q2, 2023 Results on Aug 02, 2023 Jul 22
Now 25% undervalued Jun 16 Pacific Biosciences of California, Inc. Announces Board Changes
VP & Chief Accounting Officer recently sold €60k worth of stock May 23
Insufficient new directors May 09
Full year 2022 earnings released: US$1.40 loss per share (vs US$0.89 loss in FY 2021) Feb 19
PacBio to Expand MAS-Seq Technology to 16S rRNA and Bulk RNA-Seq Solutions Feb 08
Pacific Biosciences of California, Inc. to Report Q4, 2022 Results on Feb 16, 2023 Feb 03
Insufficient new directors Jan 26 Pacific Biosciences of California, Inc. has completed a Follow-on Equity Offering in the amount of $175 million. Jan 26
Pacific Biosciences of California, Inc. has completed a Follow-on Equity Offering in the amount of $175 million. Jan 25
Pacific Biosciences of California, Inc. Provides Revenue Guidance for Fourth Quarter and Full Year 2022
Pacific Biosciences of California, Inc. Announces Board Appointments Nov 03
Pacific Biosciences of California, Inc. Withdraws its Financial Guidance Oct 27 Pacific Biosciences of California, Inc. to Report Q3, 2022 Results on Nov 07, 2022
PacBio Launches Single-Cell Transcriptome Solution Ushering in a New Era of RNA Discovery Oct 21
PacBio and Twist Bioscience Deliver Initial Portfolio of Target Enrichment Panels for HiFi Sequencing Oct 20
Chief Financial Officer recently sold €75k worth of stock Oct 04
PacBio Unveils A New Method for Comprehensive, Genome-Wide Tandem Repeat Analysis Sep 28
Second quarter 2022 earnings released: US$0.32 loss per share (vs US$0.21 loss in 2Q 2021) Aug 04
Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Full Year 2022 Aug 04
Pacific Biosciences of California, Inc. Appoints Jeff Eidel as Chief Commercial Officer, Effective August 16, 2022 Jul 22
Pacific Biosciences of California, Inc. to Report Q2, 2022 Results on Aug 03, 2022 Jul 19
Pacific Biosciences of California, Inc. Announces Management Changes May 19
First quarter 2022 earnings released: US$0.37 loss per share (vs US$0.45 loss in 1Q 2021) May 06
Insufficient new directors Apr 27
Pacific Biosciences of California, Inc. to Report Q1, 2022 Results on May 04, 2022 Apr 21
Pacific Biosciences of California, Inc., Annual General Meeting, May 25, 2022 Apr 15
Insufficient new directors Apr 05
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 16
Pacific Biosciences of California, Inc. to Report Q4, 2021 Results on Feb 15, 2022 Feb 02
Chief Operating Officer recently sold €519k worth of stock Jan 14
Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Fourth Quarter and the Fiscal Year Ended December 31, 2021 Jan 12
PacBio’s New HiFiViral Surveillance Kit Performance is Not Impacted by Omicron Mutations, Delivering Complete SARS-CoV-2 Genomes for All Circulating Variants Dec 29
Insufficient new directors Dec 06
Third quarter 2021 earnings released: EPS US$0.082 (vs US$0.14 loss in 3Q 2020) Nov 03 Pacific Biosciences of California, Inc. (NasdaqGS:PACB) completed the acquisition of Omniome, Inc.
Pacific Biosciences of California, Inc. (NasdaqGS:PACB) acquired Circulomics, Inc. Aug 05
Second quarter 2021 earnings released: US$0.21 loss per share (vs US$0.15 loss in 2Q 2020) Aug 04
Senior Fellow & Director Michael Hunkapiller has left the company Jun 18
VP & Chief Accounting Officer has left the company May 19
First quarter 2021 earnings released: US$0.45 loss per share (vs US$0.008 profit in 1Q 2020) May 01
Pacific Biosciences of California, Inc. Launches New HiFi Sequencing Workflow Apr 27
Revenue beats expectations Mar 02
Full year 2020 earnings released: EPS US$0.18 (vs US$0.55 loss in FY 2019) Mar 02
VP & Chief Accounting Officer recently sold €124k worth of stock Feb 27
Pacific Biosciences Sequel II Systems Deployed to Scale-Up Global Viral Surveillance Initiatives Focused on COVID-19 Feb 19
Independent Director recently sold €4.2m worth of stock Feb 19
Pacific Biosciences of California, Inc. announced that it has received $900 million in funding from SB Northstar LP Feb 18
Full year 2020 earnings released: EPS US$0.18 (vs US$0.55 loss in FY 2019) Feb 12
Revenue beats expectations Feb 12
New 90-day high: €42.00 Feb 12
Pacific Biosciences of California, Inc. announced that it expects to receive $900 million in funding from SB Northstar LP Feb 11
Pacific Biosciences of California, Inc., Annual General Meeting, Jun 16, 2021 Feb 10 Shareholder Returns P09 DE Life Sciences DE Market 7D -1.5% 0.1% 0.3% 1Y -80.0% -5.3% 6.9%
See full shareholder returns
Return vs Market: P09 underperformed the German Market which returned 7.2% over the past year.
Price Volatility Is P09's price volatile compared to industry and market? P09 volatility P09 Average Weekly Movement 19.7% Life Sciences Industry Average Movement 7.0% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.8% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: P09's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: P09's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Founded Employees CEO Website 2000 796 Christian O. Henry www.pacb.com
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides.
Show more Pacific Biosciences of California, Inc. Fundamentals Summary How do Pacific Biosciences of California's earnings and revenue compare to its market cap? P09 fundamental statistics Market cap €490.49m Earnings (TTM ) -€379.61m Revenue (TTM ) €166.72m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) P09 income statement (TTM ) Revenue US$173.15m Cost of Revenue US$118.91m Gross Profit US$54.23m Other Expenses US$448.47m Earnings -US$394.24m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.44 Gross Margin 31.32% Net Profit Margin -227.69% Debt/Equity Ratio 197.1%
How did P09 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/30 11:13 End of Day Share Price 2024/12/30 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Pacific Biosciences of California, Inc. is covered by 24 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Luke Sergott Barclays Kyle Mikson Canaccord Genuity Bryan Brokmeier Cantor Fitzgerald & Co.
Show 21 more analysts 
